Trial · NCT04498832
Results by group114
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 114
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-HD | A/H1N1 | 309.0 | 95% Confidence Interval 282.1 to 338.4 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-SD | A/H1N1 | 110.0 | 95% Confidence Interval 100.0 to 121.1 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-HD | A/H3N2-like | 540.0 | 95% Confidence Interval 504.4 to 578.0 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-SD | A/H3N2-like | 239.9 | 95% Confidence Interval 222.0 to 259.1 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-HD | B/Victoria-like | 354.8 | 95% Confidence Interval 333.0 to 378.0 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-SD | B/Victoria-like | 139.2 | 95% Confidence Interval 129.4 to 149.8 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-HD | B/Yamagata | 795.8 | 95% Confidence Interval 750.3 to 844.1 | titers |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 | QIV-SD | B/Yamagata | 254.7 | 95% Confidence Interval 237.7 to 273.0 | titers |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-HD | A/H1N1 | 77.6 | 95% Confidence Interval 75.0 to 80.1 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-SD | A/H1N1 | 47.9 | 95% Confidence Interval 44.9 to 51.0 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-HD | A/H3N2-like | 75.4 | 95% Confidence Interval 72.6 to 77.9 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-SD | A/H3N2-like | 47.3 | 95% Confidence Interval 44.2 to 50.4 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-HD | B/Victoria-like | 79.2 | 95% Confidence Interval 76.6 to 81.6 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-SD | B/Victoria-like | 47.8 | 95% Confidence Interval 44.7 to 50.8 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-HD | B/Yamagata | 74.4 | 95% Confidence Interval 71.7 to 77.1 | percentage of participants |
| Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis | QIV-SD | B/Yamagata | 39.0 | 95% Confidence Interval 36.1 to 42.1 | percentage of participants |
| GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28 | QIV-HD | A/H1N1: Day 0 | 14.5 | 95% Confidence Interval 13.5 to 15.5 | titers |
| GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28 | QIV-SD | A/H1N1: Day 0 | 14.9 | 95% Confidence Interval 13.9 to 16.1 | titers |
| GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28 | QIV-HD | A/H1N1: Day 28 | 309.0 | 95% Confidence Interval 282.1 to 338.4 | titers |
| GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28 | QIV-SD | A/H1N1: Day 28 | 110.0 | 95% Confidence Interval 100.0 to 121.1 | titers |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04498832/results